Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV).
Identifieur interne : 002562 ( PubMed/Curation ); précédent : 002561; suivant : 002563Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV).
Auteurs : Szu-Chia Lai [Taïwan] ; Pele Choi-Sing Chong ; Chia-Tsui Yeh ; Levent Shih-Jen Liu ; Jia-Tsrong Jan ; Hsiang-Yun Chi ; Hwan-Wun Liu ; Ann Chen ; Yeau-Ching WangSource :
- Journal of biomedical science [ 1021-7770 ] ; 2005.
Descripteurs français
- KwdFr :
- Amorces ADN, Animaux, Anticorps monoclonaux (), Anticorps monoclonaux (immunologie), Données de séquences moléculaires, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (), Glycoprotéines membranaires (immunologie), Protéines de l'enveloppe virale (), Protéines de l'enveloppe virale (immunologie), Souris, Souris de lignée BALB C, Séquence d'acides aminés, Séquence nucléotidique, Technique d'immunofluorescence indirecte, Technique de Western, Test ELISA, Test de retard de migration électrophorétique, Tests de neutralisation, Virus du SRAS (immunologie), Épitopes (), Épitopes (immunologie).
- MESH :
- immunologie : Anticorps monoclonaux, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Virus du SRAS, Épitopes.
- Amorces ADN, Animaux, Anticorps monoclonaux, Données de séquences moléculaires, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Souris, Souris de lignée BALB C, Séquence d'acides aminés, Séquence nucléotidique, Technique d'immunofluorescence indirecte, Technique de Western, Test ELISA, Test de retard de migration électrophorétique, Tests de neutralisation, Épitopes.
English descriptors
- KwdEn :
- Amino Acid Sequence, Animals, Antibodies, Monoclonal (chemistry), Antibodies, Monoclonal (immunology), Base Sequence, Blotting, Western, DNA Primers, Electrophoretic Mobility Shift Assay, Enzyme-Linked Immunosorbent Assay, Epitopes (chemistry), Epitopes (immunology), Fluorescent Antibody Technique, Indirect, Membrane Glycoproteins (chemistry), Membrane Glycoproteins (immunology), Mice, Mice, Inbred BALB C, Molecular Sequence Data, Neutralization Tests, SARS Virus (immunology), Spike Glycoprotein, Coronavirus, Viral Envelope Proteins (chemistry), Viral Envelope Proteins (immunology).
- MESH :
- chemical , chemistry : Antibodies, Monoclonal, Epitopes, Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , immunology : Antibodies, Monoclonal, Epitopes, Membrane Glycoproteins, Viral Envelope Proteins.
- immunology : SARS Virus.
- Amino Acid Sequence, Animals, Base Sequence, Blotting, Western, DNA Primers, Electrophoretic Mobility Shift Assay, Enzyme-Linked Immunosorbent Assay, Fluorescent Antibody Technique, Indirect, Mice, Mice, Inbred BALB C, Molecular Sequence Data, Neutralization Tests, Spike Glycoprotein, Coronavirus.
Abstract
The spike (S) glycoprotein is thought to play a complex and central role in the biology and pathogenesis of SARS coronavirus infection. In this study, a recombinant protein (rS268, corresponding to residues 268-1255 of SARS-CoV S protein) was expressed in Escherichia coli and was purified to near homogeneity. After immunization with rS268, S protein-specific BALB/c antisera and mAbs were induced and confirmed using ELISA, Western blot and IFA. Several BALB/c mAbs were found to be effectively to neutralize the infection of Vero E6 cells by SARS-CoV in a dose-dependent manner. Systematic epitope mapping showed that all these neutralizing mAbs recognized a 15-residues peptide (CB-119) corresponding to residues 1143-1157 (SPDVDLGDISGINAS) that was located to the second heptad repeat (HR2) region of the SARS-CoV spike protein. The peptide CB-119 could specifically inhibit the interaction of neutralizing mAbs and spike protein in a dose-dependent manner. Further, neutralizing mAbs, but not control mAbs, could specifically interact with CB-119 in a dose-dependent manner. Results implicated that the second heptad repeat region of spike protein could be a good target for vaccine development against SARS-CoV.
DOI: 10.1007/s11373-005-9004-3
PubMed: 16132115
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002562
Links to Exploration step
pubmed:16132115Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV).</title>
<author><name sortKey="Lai, Szu Chia" sort="Lai, Szu Chia" uniqKey="Lai S" first="Szu-Chia" last="Lai">Szu-Chia Lai</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Preventive Medicine, National Defense Medical Center, 90048-700, San-Hsia, Taipei, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Institute of Preventive Medicine, National Defense Medical Center, 90048-700, San-Hsia, Taipei</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chong, Pele Choi Sing" sort="Chong, Pele Choi Sing" uniqKey="Chong P" first="Pele Choi-Sing" last="Chong">Pele Choi-Sing Chong</name>
</author>
<author><name sortKey="Yeh, Chia Tsui" sort="Yeh, Chia Tsui" uniqKey="Yeh C" first="Chia-Tsui" last="Yeh">Chia-Tsui Yeh</name>
</author>
<author><name sortKey="Liu, Levent Shih Jen" sort="Liu, Levent Shih Jen" uniqKey="Liu L" first="Levent Shih-Jen" last="Liu">Levent Shih-Jen Liu</name>
</author>
<author><name sortKey="Jan, Jia Tsrong" sort="Jan, Jia Tsrong" uniqKey="Jan J" first="Jia-Tsrong" last="Jan">Jia-Tsrong Jan</name>
</author>
<author><name sortKey="Chi, Hsiang Yun" sort="Chi, Hsiang Yun" uniqKey="Chi H" first="Hsiang-Yun" last="Chi">Hsiang-Yun Chi</name>
</author>
<author><name sortKey="Liu, Hwan Wun" sort="Liu, Hwan Wun" uniqKey="Liu H" first="Hwan-Wun" last="Liu">Hwan-Wun Liu</name>
</author>
<author><name sortKey="Chen, Ann" sort="Chen, Ann" uniqKey="Chen A" first="Ann" last="Chen">Ann Chen</name>
</author>
<author><name sortKey="Wang, Yeau Ching" sort="Wang, Yeau Ching" uniqKey="Wang Y" first="Yeau-Ching" last="Wang">Yeau-Ching Wang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:16132115</idno>
<idno type="pmid">16132115</idno>
<idno type="doi">10.1007/s11373-005-9004-3</idno>
<idno type="wicri:Area/PubMed/Corpus">002562</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002562</idno>
<idno type="wicri:Area/PubMed/Curation">002562</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002562</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV).</title>
<author><name sortKey="Lai, Szu Chia" sort="Lai, Szu Chia" uniqKey="Lai S" first="Szu-Chia" last="Lai">Szu-Chia Lai</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Preventive Medicine, National Defense Medical Center, 90048-700, San-Hsia, Taipei, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Institute of Preventive Medicine, National Defense Medical Center, 90048-700, San-Hsia, Taipei</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chong, Pele Choi Sing" sort="Chong, Pele Choi Sing" uniqKey="Chong P" first="Pele Choi-Sing" last="Chong">Pele Choi-Sing Chong</name>
</author>
<author><name sortKey="Yeh, Chia Tsui" sort="Yeh, Chia Tsui" uniqKey="Yeh C" first="Chia-Tsui" last="Yeh">Chia-Tsui Yeh</name>
</author>
<author><name sortKey="Liu, Levent Shih Jen" sort="Liu, Levent Shih Jen" uniqKey="Liu L" first="Levent Shih-Jen" last="Liu">Levent Shih-Jen Liu</name>
</author>
<author><name sortKey="Jan, Jia Tsrong" sort="Jan, Jia Tsrong" uniqKey="Jan J" first="Jia-Tsrong" last="Jan">Jia-Tsrong Jan</name>
</author>
<author><name sortKey="Chi, Hsiang Yun" sort="Chi, Hsiang Yun" uniqKey="Chi H" first="Hsiang-Yun" last="Chi">Hsiang-Yun Chi</name>
</author>
<author><name sortKey="Liu, Hwan Wun" sort="Liu, Hwan Wun" uniqKey="Liu H" first="Hwan-Wun" last="Liu">Hwan-Wun Liu</name>
</author>
<author><name sortKey="Chen, Ann" sort="Chen, Ann" uniqKey="Chen A" first="Ann" last="Chen">Ann Chen</name>
</author>
<author><name sortKey="Wang, Yeau Ching" sort="Wang, Yeau Ching" uniqKey="Wang Y" first="Yeau-Ching" last="Wang">Yeau-Ching Wang</name>
</author>
</analytic>
<series><title level="j">Journal of biomedical science</title>
<idno type="ISSN">1021-7770</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Antibodies, Monoclonal (chemistry)</term>
<term>Antibodies, Monoclonal (immunology)</term>
<term>Base Sequence</term>
<term>Blotting, Western</term>
<term>DNA Primers</term>
<term>Electrophoretic Mobility Shift Assay</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>Epitopes (chemistry)</term>
<term>Epitopes (immunology)</term>
<term>Fluorescent Antibody Technique, Indirect</term>
<term>Membrane Glycoproteins (chemistry)</term>
<term>Membrane Glycoproteins (immunology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Molecular Sequence Data</term>
<term>Neutralization Tests</term>
<term>SARS Virus (immunology)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Envelope Proteins (chemistry)</term>
<term>Viral Envelope Proteins (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Amorces ADN</term>
<term>Animaux</term>
<term>Anticorps monoclonaux ()</term>
<term>Anticorps monoclonaux (immunologie)</term>
<term>Données de séquences moléculaires</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires ()</term>
<term>Glycoprotéines membranaires (immunologie)</term>
<term>Protéines de l'enveloppe virale ()</term>
<term>Protéines de l'enveloppe virale (immunologie)</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Séquence d'acides aminés</term>
<term>Séquence nucléotidique</term>
<term>Technique d'immunofluorescence indirecte</term>
<term>Technique de Western</term>
<term>Test ELISA</term>
<term>Test de retard de migration électrophorétique</term>
<term>Tests de neutralisation</term>
<term>Virus du SRAS (immunologie)</term>
<term>Épitopes ()</term>
<term>Épitopes (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Epitopes</term>
<term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Epitopes</term>
<term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps monoclonaux</term>
<term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Virus du SRAS</term>
<term>Épitopes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Base Sequence</term>
<term>Blotting, Western</term>
<term>DNA Primers</term>
<term>Electrophoretic Mobility Shift Assay</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>Fluorescent Antibody Technique, Indirect</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Molecular Sequence Data</term>
<term>Neutralization Tests</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Amorces ADN</term>
<term>Animaux</term>
<term>Anticorps monoclonaux</term>
<term>Données de séquences moléculaires</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Séquence d'acides aminés</term>
<term>Séquence nucléotidique</term>
<term>Technique d'immunofluorescence indirecte</term>
<term>Technique de Western</term>
<term>Test ELISA</term>
<term>Test de retard de migration électrophorétique</term>
<term>Tests de neutralisation</term>
<term>Épitopes</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The spike (S) glycoprotein is thought to play a complex and central role in the biology and pathogenesis of SARS coronavirus infection. In this study, a recombinant protein (rS268, corresponding to residues 268-1255 of SARS-CoV S protein) was expressed in Escherichia coli and was purified to near homogeneity. After immunization with rS268, S protein-specific BALB/c antisera and mAbs were induced and confirmed using ELISA, Western blot and IFA. Several BALB/c mAbs were found to be effectively to neutralize the infection of Vero E6 cells by SARS-CoV in a dose-dependent manner. Systematic epitope mapping showed that all these neutralizing mAbs recognized a 15-residues peptide (CB-119) corresponding to residues 1143-1157 (SPDVDLGDISGINAS) that was located to the second heptad repeat (HR2) region of the SARS-CoV spike protein. The peptide CB-119 could specifically inhibit the interaction of neutralizing mAbs and spike protein in a dose-dependent manner. Further, neutralizing mAbs, but not control mAbs, could specifically interact with CB-119 in a dose-dependent manner. Results implicated that the second heptad repeat region of spike protein could be a good target for vaccine development against SARS-CoV.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16132115</PMID>
<DateCompleted><Year>2006</Year>
<Month>01</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1021-7770</ISSN>
<JournalIssue CitedMedium="Print"><Volume>12</Volume>
<Issue>5</Issue>
<PubDate><Year>2005</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of biomedical science</Title>
<ISOAbbreviation>J. Biomed. Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV).</ArticleTitle>
<Pagination><MedlinePgn>711-27</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The spike (S) glycoprotein is thought to play a complex and central role in the biology and pathogenesis of SARS coronavirus infection. In this study, a recombinant protein (rS268, corresponding to residues 268-1255 of SARS-CoV S protein) was expressed in Escherichia coli and was purified to near homogeneity. After immunization with rS268, S protein-specific BALB/c antisera and mAbs were induced and confirmed using ELISA, Western blot and IFA. Several BALB/c mAbs were found to be effectively to neutralize the infection of Vero E6 cells by SARS-CoV in a dose-dependent manner. Systematic epitope mapping showed that all these neutralizing mAbs recognized a 15-residues peptide (CB-119) corresponding to residues 1143-1157 (SPDVDLGDISGINAS) that was located to the second heptad repeat (HR2) region of the SARS-CoV spike protein. The peptide CB-119 could specifically inhibit the interaction of neutralizing mAbs and spike protein in a dose-dependent manner. Further, neutralizing mAbs, but not control mAbs, could specifically interact with CB-119 in a dose-dependent manner. Results implicated that the second heptad repeat region of spike protein could be a good target for vaccine development against SARS-CoV.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lai</LastName>
<ForeName>Szu-Chia</ForeName>
<Initials>SC</Initials>
<AffiliationInfo><Affiliation>Institute of Preventive Medicine, National Defense Medical Center, 90048-700, San-Hsia, Taipei, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chong</LastName>
<ForeName>Pele Choi-Sing</ForeName>
<Initials>PC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yeh</LastName>
<ForeName>Chia-Tsui</ForeName>
<Initials>CT</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Levent Shih-Jen</ForeName>
<Initials>LS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jan</LastName>
<ForeName>Jia-Tsrong</ForeName>
<Initials>JT</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chi</LastName>
<ForeName>Hsiang-Yun</ForeName>
<Initials>HY</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Hwan-Wun</ForeName>
<Initials>HW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Ann</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Yeau-Ching</ForeName>
<Initials>YC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2005</Year>
<Month>11</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Biomed Sci</MedlineTA>
<NlmUniqueID>9421567</NlmUniqueID>
<ISSNLinking>1021-7770</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000939">Epitopes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D024202" MajorTopicYN="N">Electrophoretic Mobility Shift Assay</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019084" MajorTopicYN="N">Fluorescent Antibody Technique, Indirect</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year>
<Month>04</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2005</Year>
<Month>06</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>9</Month>
<Day>1</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>1</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>9</Month>
<Day>1</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16132115</ArticleId>
<ArticleId IdType="doi">10.1007/s11373-005-9004-3</ArticleId>
<ArticleId IdType="pmc">PMC7089214</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Biotechnology. 1992;24:524-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1422065</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>EMBO J. 1995 Nov 15;14(22):5524-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8521809</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol Methods. 2001 Aug;96(2):107-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11445142</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1993 Mar;67(3):1185-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7679743</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FEBS Lett. 2003 Feb 11;536(1-3):56-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12586338</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 1990 Apr;175(2):548-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2158184</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1990 Feb;64(2):731-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1688627</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 1992 Mar;187(1):178-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1310555</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2003 Aug;77(16):8801-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12885899</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2002 Sep;76(18):9079-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12186891</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Jul 2;319(3):746-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15184046</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15150417</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 1997 Nov 24;238(2):291-304</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9400602</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Microb Pathog. 2001 Sep;31(3):145-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11500099</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 2004 May 14;279(20):20836-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14996844</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 1988 Sep;11(2):141-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2462314</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2003 Mar;77(5):3281-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12584351</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vet Res. 1993;24(2):125-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8393722</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1997 Nov;71(11):8490-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9343206</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 2002 Apr 19;277(16):14238-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11859089</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14172-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11106388</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Diagn Lab Immunol. 2003 May;10(3):451-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12738648</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7287-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9636141</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 1998 Oct 16;273(42):27182-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9765238</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Jun 18;319(1):283-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15158473</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2004 Mar 20;363(9413):938-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15043961</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14983044</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochemistry. 2004 Nov 9;43(44):14064-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15518555</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002562 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002562 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:16132115 |texte= Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV). }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16132115" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |